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Abstract
Purpose The objective of this study was to explore the feasibility of harmonising performance for PET/CT systems equipped
with time-of-flight (ToF) and resolution modelling/point spread function (PSF) technologies. A second aim was producing a
working prototype of new harmonising criteria with higher contrast recoveries than current EARL standards using various SUV
metrics.
Methods Four PET/CT systems with both ToF and PSF capabilities from three major vendors were used to acquire and
reconstruct images of the NEMA NU2–2007 body phantom filled conforming EANM EARL guidelines. A total of 15 recon-
struction parameter sets of varying pixel size, post filtering and reconstruction type, with three different acquisition durations
were used to compare the quantitative performance of the systems. A target range for recovery curves was established such that it
would accommodate the highest matching recoveries from all investigated systems. These updated criteria were validated on 18
additional scanners from 16 sites in order to demonstrate the scanners’ ability to meet the new target range.
Results Each of the four systems was found to be capable of producing harmonising reconstructions with similar recovery curves.
The five reconstruction parameter sets producing harmonising results significantly increased SUVmean (25%) and SUVmax
(26%) contrast recoveries compared with current EARL specifications. Additional prospective validation performed on 18
scanners from 16 EARL accredited sites demonstrated the feasibility of updated harmonising specifications. SUVpeak was
found to significantly reduce the variability in quantitative results while producing lower recoveries in smaller (≤17mmdiameter)
sphere sizes.
Conclusions Harmonising PET/CTsystems with ToF and PSF technologies from different vendors was found to be feasible. The
harmonisation of such systems would require an update to the current multicentre accreditation program EARL in order to
accommodate higher recoveries. SUVpeak should be further investigated as a noise resistant alternative quantitative metric to
SUVmax.
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Introduction
18F–fluorodeoxyglucose (18F–FDG) positron emission tomog-
raphy (PET) and computed tomography (CT) hybrid imaging
(PET/CT) is an important functional imaging tool being widely
used for diagnosis, staging and therapy response evaluation in,
e.g., oncology [1–20]. Combined anatomical and functional in-
formation can be obtained in one session using hybrid PET/CT.
In clinical practice, visual inspection of PET/CT images might
be sufficient for the purposes of staging or restaging [7, 21],
however PET is a quantitative technique [22–26] and can pro-
vide more accurate and less observer-dependent metrics for di-
agnosis, therapy assessment and response monitoring using
quantitative data in addition to visual interpretation [27]. In re-
cent oncological clinical trials quantitative PET/CT data are also
used for patient selection, stratification and therapy response
monitoring. However, variability, reproducibility and accuracy
of quantitative PET/CT imaging [28–34] have to be considered.
Scientific societies such as the European Association of Nuclear
Medicine (EANM), American College of Radiology (ACR),
American Association of Physicists in Medicine (AAPM),
Radiological Society of North America (RSNA) and Society
of Nuclear Medicine and Molecular Imaging (SNMMI) are
closely collaborating to promote standardisation of practices in
order to reduce variability of quantification in multicentre clin-
ical trials. Initiatives such as QIBA-UPICT, SNMMI-CTN and
EANM-EARL are providing quality control programs to assure
quantitative comparability [35–40].
High utilisation of PET/CT in oncology can be attributed to
the availability of 18F–FDG [5, 41]. Dynamic PET scans and
pharmacokinetic modelling to evaluate the rate of glucose
metabolism of tumours is an excellent method for quantifica-
tion [27] but the technical impediments such as the limited
scanner field of view and increased scan acquisition time
make it unfeasible for routine use [42]. In clinical practice, a
simplified uptake metric such as the standard uptake value
(SUV) [43, 44] is therefore most commonly used. While
SUVanalysis is relatively easy to apply, it suffers from multi-
ple technical, physical and biological factors that can signifi-
cantly affect quantification [27]. The required level of
harmonisation depends on the intended use of the PET study.
When the same PET/CTsystem is used for therapy assessment
and based on relative changes in SUV before and after thera-
py, a high reproducibility rather than absolute accuracy might
be most important. It has been shown that in this case, when
the scanner performance remains unchanged over time, con-
sistent application of a certain methodology could be suffi-
cient [34, 45]. However, patients are often scanned on differ-
ent PET/CT systems, either because the scanner had been
replaced by a new one, or in different institutions, which
makes accurate cross-calibration of systems a crucial require-
ment. Absolute quantitative measures (e.g., residual uptake of
18F–FDG after therapy session) are also being used for
differentiation between malignant and benign lesions, deter-
mining prognosis and response monitoring [27]. This again
requires high reproducibility and comparability of the quanti-
tative data, especially in multicentre settings.
One of the challenges in PET/CT systems performance
harmonisation is the variability caused by different PET/CT
technologies available in the field. Multicentre standards
should not be based on the less performing systems; they need
to fit with the highest, yet common denominator in systems’
performance. Additionally, in case of optimization of PET/CT
systems performance for lesion detection, a single centre
quantification does not necessarily coincide with a multicentre
one. A particular challenge for recent PET/CT systems result-
ed from the introduction of time-of-flight (ToF) and resolution
modelling (point spread function (PSF)) capabilities. The lat-
ter increased tumour detectability but also caused higher var-
iability across centres, since some have and others lack these
technologies. Currently a large number of the EARL
accredited PET/CT systems [46] do not have PSF image re-
construction capabilities. However, it is expected that over the
next couple of years the majority of the PET/CT systems will
be equipped with these new reconstruction techniques.
The aim of this paper is to explore the feasibility of
harmonising performance of PET/CT systems equipped with




Four PET/CT systems equipped with both ToF and PSF capa-
bilities from three major vendors (General Electric (GE),
Siemens and Philips) were selected for this study. Systems
included were the Siemens Biograph mCT (Siemens system
1), the Siemens Biograph mCT Flow (Siemens system 2), the
GE Discovery 710 (GE system) and the Philips Ingenuity TF
128 (Philips system). The equipment was calibrated in accor-
dance with the corresponding manufacturer’s instructions. In
addition, all systems were participating and accredited in the
EANM/EARL 18F–FDG PET/CT accreditation program.
Detailed specifications for the systems can be found in sup-
plemental Table 1 and references [47–51].
Phantom experiments
The phantoms and filling procedures used complied with the
EANM/EARL guidelines for Image Quality QCmeasurements
which need to be performed annually as part of the EANM/
EARL accreditation program [35]. The NEMA NU2–2007
body phantom was used, which is a plastic cylinder in the form
of a fillable torso cavity, to act as a background compartment. It
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has a 5 cm diameter cylindrical lung insert in the centre and six
fillable spheres with internal diameters of 10, 13, 17, 22, 28 and
37 mm, positioned coaxially around the lung insert. The lung
insert is filled with polystyrene beads in order to mimic lung
tissue. The phantom background compartment and the spheri-
cal inserts were filled with 18F–FDG solutions aimed at activ-
ity concentrations of 2 kBq/mL and 20 kBq/mL, respectively,
at the start of the measurements, resulting in a sphere to back-
ground activity concentration ratio of 10:1.
Acquisition and reconstruction parameters
In accordance with current EANM/EARL guidelines for 18F–
FDG Image Quality QC phantom imaging [35], a low dose CT
acquisition, followed by an emission scan consisting of two bed
positions with an acquisition time of 5min per bed position is to
be acquired for the Bimage quality^ dataset to assess contrast
recovery performance. In this study, acquisition time of 5 min
per bed position was selected as the reference for high count
statistics. In order to investigate the effect of reduced count
statistics on contrast recovery, data acquired with shorter acqui-
sition times, respectively 2 and 1 min per bed position, were
collected. The GE and Philips systems had list mode data ac-
quisition capability available, which meant that only the 5 min/
bed position emission scans were acquired and reconstructions
with shorter acquisition times were generated retrospectively
from the list mode data. On the Siemens systems included in
this study, multiple shorter emission scans were acquired with
the phantom left in an unchanged position. In order to facilitate
the Siemens Flow system’s (Siemens system 2) possibility of
performing scanning with continuous table movement, instead
of a specific bed position scanning duration, table feed speeds
of 0.5 mm/s, 1 mm/s and 2 mm/s were selected, resulting in
similar acquisition times as with the other scanners.
Reconstructions were performed using the software avail-
able on each of the PET/CT systems. TOF, PSF, normalisa-
tion, randoms, scatter and attenuation corrections were applied
and the reconstruction parameters were selected to increase
overall contrast recovery, meanwhile aiming at achieving
comparable recovery values across systems (for each sphere).
In addition, we also considered achieving comparable recov-
ery values between the spheres to minimise severe partial
volume effects as well as large Gibbs overshoots. Clinically
used and vendor recommended reconstruction parameters
were applied and varied. Three iterations with 21 subsets were
used for Siemens 1 (Biograph mCT) and two iterations with
21 subsets for Siemens 2 (mCT Flow) reconstruction. For GE
- B, D, F and G (Discovery 710) - two iterations with 24
subsets and the VPFXS reconstruction method were used,
while for GE - A, C and E - the QCFX reconstruction method,
with an unknown number of iterations and subsets, was used.
For the Philips systems the iterations/subsets were 3/33 but
these could not be selected prior to scanning, with no values
retrieved from the DICOM header of the images; so the
BLOB OS TF reconstruction method was used. Different
Gaussian filters and pixel sizes within clinically relevant
ranges were also investigated in order to study their effects
on contrast recovery. Additionally, for the GE system, a pro-
prietary reconstruction method, the BQ.Clear^, which uses a
Bayesian penalised-likelihood reconstruction algorithm, was
investigated using different penalization factors (β) and its
effect on quantitative image quality was evaluated. Due to
differences among vendors and models, the available recon-
struction parameters and their ranges were limited based on
availability and/or user selectability. In total, 15 reconstruction
parameter sets (reconstruction modes) were used to assess and
compare the quantitative performance of the investigated sys-
tems. Each reconstruction mode was applied on three different
scans, acquired with long (~4 min/bed for the Siemens Flow
system; ~5 min/bed for all other systems), with medium
(~2 min/bed) and short (~1 min/bed) frame durations. A sum-
mary of the acquisition and reconstruction settings of the 15
reconstruction modes is presented in Table 1.
Data analysis
Data reconstructed on the PET/CT were exported to a PC for
further analysis using the EARL semi-automatic tool [35] de-
signed for quantitative analysis of images of the NEMA NU2–
2007 body phantom, filled conforming to EANM/EARL
guidelines for 18F–FDG Image Quality QC phantom imaging.
The software tool requires phantom images in DICOM format
and filling data as input, and extracts SUV recovery for the
spheres, a calibration factor for the background compartment
and standard deviation and coefficients of variation from uni-
form images of the background. The SUV recovery coefficient
(RC) is defined as the ratio between measured and expected
activity concentration in each spherical insert. RC values were
calculated based on 50% background corrected isocontour VOI
(RCSUVmean), maximum voxel value included in VOI
(RCSUVmax) and spherical VOI with a diameter of 12 mm, po-
sitioned so to yield the highest uptake (RCSUVpeak) [35, 39, 52].
Prior to further analysis, all data were corrected for system
calibration bias in order to be able to compare the various recon-
struction modes’ impact on RCs and not to be effected by inter-
scanner calibration errors. For this purpose, to all RCs a correc-
tion factor, defined as the ratio between expected and measured
activity concentration in the corresponding uniform background
compartment, was applied. For the 15 initial reconstruction
modes, inter-scanner global correction factors ranged from
0.88 to 1.12, with the mean and standard deviation being 0.98
and 0.055, respectively. Intra-scanner changes were below 1%.
For the 23 additional reconstructions, the inter-scanner global
correction factors ranged from 0.93 to 1.10 (one system, how-
ever, showed a correction factor of 0.8), with the mean and
standard deviation values of 0.99 and 0.055, respectively.
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Selection of harmonising reconstruction modes
The primary objective of this study was to find reconstruction
modes providing high, yet uniform contrast recoveries within
the spheres of the NEMA NU2–2007 body phantom, which
could be matched across all generations of PET/CT systems
currently used in clinical practice – which would result in
quantitative harmonisation of PET/CT systems.
RCSUVmean, RCSUVmax and RCSUVpeak curves for all recon-
structed phantom images were plotted against sphere diame-
ters (Fig. 1) and characterised using visual and quantitative
analysis, for which the applied metrics are summarised in
Table 2. Reconstruction modes with higher RCs than current
EARL specifications, as well as tightly grouped and stable
RCSUVmean and RCSUVmax curves, were sought for
harmonisation purposes.
The harmonising reconstruction modes were selected by
simultaneously analysing quantitative characteristics of the
reconstruction modes along with visual appearance of the
RC curves. The following considerations were kept in mind
while determining feasible reconstruction modes – (1) the
proposed harmonising specifications should provide an in-
crease over the current EARL compliant RC values, (2) the
bandwidth of RCs should be similar to the current Earl spec-
ification limits and (3) the harmonising RC curves should not
demonstrate major overshoots (=upward bias) due to Gibbs
artefacts. While the harmonising reconstruction modes were
selected based on the abovementioned considerations, quanti-
tative cut-off criteria were retrospectively determined and stat-
ed in Table 9 based on the bandwidth and characteristics of
harmonising reconstruction modes. Performances of the can-
didate reconstruction modes were compared with the initial
group of reconstructions as well as current EARL accredita-
tion specifications.
Mean contrast recovery (MCR)
Mean contrast recovery (MCR) was calculated in order to
evaluate overall contrast recovery potential of a reconstruction
mode while Coefficient of Variation of the MCR parameter
(CoVMCR) was used to characterise agreement among various
reconstruction modes’ RC curves. Increased coinciding MCR
and reduced CoVMCR values were preferred.
Contrast recovery variability (CRV)
Contrast Recovery Variability (CRVmedium and CRVshort) pa-
rameters were used to evaluate a reconstruction mode’s ability
to produce consistent results in case of reduced count statis-
tics. In order to achieve it, RCs of short and medium time
frame acquisitions were compared to the long acquisition’s
corresponding spheres’ RCs and relative differences calculat-
ed. Lower values were deemed preferable as being indicative
of reconstruction mode’s stability and reduced variability in
noisy environments.
Noise
Image noise was quantitatively evaluated by measuring the
Coefficient of Variation (%, SD/Mean*100) in the uniform
background compartment (CoVBG) for each reconstruction
mode and acquisition time frame. CoVBG cut-off limit of
15%, based on the existing EARL guideline and UPICT [35,
37, 40], was implemented to determine suitable reconstruction

















GE - A N/A 200 2.73 3.27 300 120 60
GE - B 0 N/A 2.73 3.27 300 120 60
GE - C N/A 350 2.73 3.27 300 120 60
GE - D 3 N/A 2.73 3.27 300 120 60
GE - E N/A 800 2.73 3.27 300 120 60
GE - F 5 N/A 2.73 3.27 300 120 60
GE - G 6.4 N/A 2.73 3.27 300 120 60
Philips - A N/A N/A 2.00 2.00 301 120 60
Philips - B N/A N/A 4.00 4.00 301 120 60
Siemens 1 - A 0 N/A 2.04 2.00 300 120 60
Siemens 1 - B 0 N/A 1.59 2.00 300 120 60
Siemens 1 - C 3 N/A 2.04 2.00 300 120 60
Siemens 1 - D 5 N/A 2.04 2.00 300 120 60
Siemens 1 - E 6.5 N/A 3.18 2.00 300 120 60
Siemens 2 - A 5 N/A 4.07 5.00 223 111 56
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modes for harmonisation. Reconstruction modes providing
lower noise images were deemed preferable.
Curvature and absolute error
Curvature and absolute error parameters were used to evaluate
RC variability and absolute accuracy of RC measurements due
to changes in sphere/lesion size. Reduced values were prefera-
ble, but similar magnitude across systems/reconstructions was
given priority.
Visual analysis
Visual analysis of the RC curves was used to identify recon-
struction modes that exhibited abnormal behaviour or local-
ised variations, such as exaggerated Gibbs artefacts, that were
not identified by the previously described quantitative
parameters.
The reconstruction modes, which were considered for
harmonisation based on SUVmean and SUVmax perfor-
mance, were also used to develop provisional specifications
for SUVpeak.
Validation of reconstruction modes for harmonisation
In order to prospectively evaluate the reproducibility and
inter-scanner variability of the proposed reconstruction modes
for harmonisation, 16 EARL accredited facilities, equipped
with current generation PET/CT systems, participated in the
study and provided the requested reconstructions from inde-
pendent phantom acquisitions applying acquisition and recon-
struction parameters (supplemental Table 2) identical or sim-
ilar to the reconstructions proposed for harmonisation pur-
poses. Data received from the centres was analysed in the
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Fig. 1 RC curves derived from 15 initial reconstruction modes using
SUVmean (a), SUVmax (b) and SUVpeak (c) quantitative metrics.
Only long acquisition time frame curves are displayed. GE (Q.Clear) –
blue dashed lines, GE (non-Q.Clear) – blue solid lines, Philips – red solid
lines, Siemens 1 – orange solid lines, Siemens 2 – green solid lines,
current EARL specifications – black solid lines
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Results
New specifications proposed for harmonisation
Analysis of the initial 15 reconstruction modes resulted in
five reconstruction modes, which produced the highest
uniform contrast recoveries and were feasible for all of
the investigated systems considering SUVmean and
SUVmax (Philips - B, GE – E, GE - F, Siemens 1 – D
and Siemens 2 – A), to be considered for harmonisation.
In order to accommodate unavoidable inter-scanner vari-
ability and reproducibility errors due to equipment
calibration and user inaccuracy, all of the RC ranges were
expanded to be proportional (i.e., using the same band-
width of performance, but taking into account increased
contrast recovery) to current EARL specifications for
sphere recoveries. Bandwidths for proposed and current
EARL specifications as well as the RC curves derived
from the five reconstruction modes are presented in
Fig. 2. For the provisional SUVpeak specifications, aver-
age sphere recoveries of the five reconstruction modes and
a bandwidth of ±2 standard deviations was used.
Additionally, recovery coefficients are plotted as a function
of background noise for each sphere and per SUVmetric
Table 2 Description of
quantitative metrics used Metric Description of metric
SUVmean Ratio of image derived average radioactivity concentration
within a region of interest and the whole body concentration
of the injected radioactivity
SUVmax Ratio of image derived maximum (single pixel) radioactivity
concentration within a region of interest and the whole body
concentration of the injected radioactivity
SUVpeak Ratio of image derived average radioactivity concentration
within a 12 mm diameter spherical volume within the region
of interest, positioned to yield the highest uptake, and the
whole body concentration of the injected radioactivity
RC Recovery Coefficient - the ratio between image derived and
expected activity concentration
MCR* Mean Contrast Recovery - mean RC of all spheres in corresponding
reconstruction mode’s long duration acquisition. Parameter is
indicative of reconstruction mode’s overall contrast
recovery potential.
CoVMCR Coefficient of Variation (SD/mean*100, %) of a group of MCR
values. Parameter is indicative of RC curves’ alignment
within a group.
CRVmedium* Contrast Recovery Variability - Mean deviation of medium
duration acquisition spheres’ RCs from the corresponding
values of long duration aquisition.
CRVshort* Contrast Recovery Variability - Mean deviation of short duration
acquisition spheres’ RCs from the corresponding values of
long duration aquisition.
CoVBG* Coefficient of Variation (SD/mean *100, %) of measured activity
concentration within the uniform background compartment of
the phantom. Parameter is indicative of the noise present
in the images.
Curvature Long acquisition duration root-mean-square deviation of spheres’
RC values from RC value of the largest (37 mm) sphere.
Parameter characterises the deviation of smaller spheres’ RC
values which usually cause the RC-object size relation to
assume a curved shape.
Absolute error Long acquisition duration root-mean-square deviation of
spheres’ RC values from unity. The parameter characterises
the reconstruction mode’s ability to report accurate activity
concentration values.
Curvature (excl. 10 mm sphere) Same as "curvature" but excluding the smallest (10 mm) sphere.
Absolute error (excl. 10 mm sphere) Same as "absolute error" but excluding the smallest (10 mm) sphere.
*Quantitative metrics that were retrospectively used to determine harmonising cut-off criteria
Eur J Nucl Med Mol Imaging (2018) 45:1344–1361 1349
(presented in supplemental Figs. 4–6). Axial slices of the
phantom data from the five harmonising reconstructions
are shown in supplemental Fig. 7.
Mean contrast recovery (MCR)
SUVmean and SUVmax RC curves vary substantially among
different systems and reconstruction modes as seen in Fig. 1
and Tables 3 and 4. The reconstruction mode showing the
lowest recoveries (Siemens 1 – E) produced a SUVmean
MCR value of 0.714 and SUVmax MCR of 0.948 while for
the highest recovery reconstruction mode (Siemens 1 – A), the
corresponding values were 1.09 and 1.56 – a difference of more
than 50%. SUVpeak MCR values were found to be between
0.754 and 0.929. CoVMCR values for the 15 reconstruction
modes were 12.4% and 15.4% for SUVmean and SUVmax,
respectively, while for SUVpeak, CoVMCR was 6.0%.
For the five reconstructionmodes proposed for harmonisation,
the range of MCR values were 0.770–0.816 and 1.01–1.09 for
SUVmean and SUVmax, respectively. The harmonising recon-
struction modes produced SUVpeakMCR values in the range of
0.784–0.823. CoVMCR values for SUVmean, SUVmax and
SUVpeak were 2.2%, 2.9% and 2.2%, respectively.
Contrast recovery variability (CRV)
The initial 15 reconstruction modes demonstrated a variable
sensitivity as a function of count statistics. The expected in-
crease in variability with decrease in count statistics was ob-
served in all reconstruction modes by comparing CRVmedium
and CRVshort values (Tables 3, 4 and 5). The CRVmedium re-
sults for SUVmean, SUVmax and SUVpeak ranged from
2.4% to 8.4%, 2.7% to 17.8% and 1.6% to 4.5%, respectively.


































































Fig. 2 RC curves derived from suggested harmonising reconstruction
modes using SUVmean (a), SUVmax (b) and SUVpeak (c) quantitative
metrics along with current EARL and possible new specifications. Only
long acquisition time frame curves are displayed. GE (Q.Clear) – blue
dashed lines, GE (non-Q.Clear) – blue solid lines, Philips – red solid lines,
Siemens 1 – orange solid lines, Siemens 2 – green solid lines, current
EARL specifications – black solid lines, possible new EARL
specifications – black dashed lines
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ranged from 2.3% to 14.5%, 4.9% to 20.4% and 2.7% to
6.3%, respectively.
For the five reconstruction modes proposed for
harmonisation, the CRVmedium results for SUVmean,
Table 3 Analysis results of 15 initial reconstruction modes using a SUVmean quantitative metric. Values found to be outside of acceptable range
during retrospective quantitative analysis, are coloured red




(excl. 10 mm 
sphere)
Absolute 
error (excl. 10 
mm sphere)
GE - A 0.956 5.0% 6.8% 0.031 0.053 0.023 0.040
GE - B 0.903 8.4% 8.7% 0.139 0.147 0.022 0.050
GE - C 0.887 6.7% 6.4% 0.109 0.140 0.025 0.077
GE - D 0.859 6.3% 6.6% 0.168 0.188 0.053 0.092
GE - E 0.806 5.2% 6.2% 0.218 0.253 0.075 0.134
GE - F 0.770 5.3% 5.3% 0.228 0.277 0.120 0.183
GE - G 0.725 3.8% 4.9% 0.253 0.321 0.147 0.228
Philips - A 0.845 3.3% 4.2% 0.149 0.192 0.088 0.134
Philips - B 0.800 2.7% 2.3% 0.236 0.271 0.124 0.165
Siemens 1 - A 1.086 6.0% 14.5% 0.097 0.117 0.108 0.125
Siemens 1 - B 1.038 3.8% 12.5% 0.072 0.076 0.071 0.081
Siemens 1 - C 0.952 3.3% 8.3% 0.111 0.101 0.048 0.043
Siemens 1 - D 0.816 2.9% 5.1% 0.197 0.222 0.097 0.138
Siemens 1 - E 0.714 2.4% 4.0% 0.269 0.329 0.166 0.238
Siemens 2 - A 0.804 3.0% 4.4% 0.203 0.238 0.100 0.150
Min 0.714 2.4% 2.3% 0.031 0.053 0.022 0.040
Max 1.086 8.4% 14.5% 0.269 0.329 0.166 0.238
Average 0.864 4.5% 6.7% 0.165 0.195 0.085 0.125
COVMCR
12.4%
Table 4 Analysis results of 15 initial reconstructionmodes using a SUVmax quantitative metric. Values found to be outside of acceptable range during
retrospective quantitative analysis, are coloured red




(excl. 10 mm 
sphere)
Absolute 
error (excl. 10 
mm sphere)
GE - A 1.245 17.8% 20.4% 0.081 0.255 0.089 0.265
GE - B 1.201 11.9% 19.7% 0.160 0.236 0.052 0.257
GE - C 1.142 12.9% 15.1% 0.076 0.157 0.036 0.172
GE - D 1.139 10.6% 15.8% 0.181 0.194 0.047 0.200
GE - E 1.036 7.2% 7.7% 0.212 0.178 0.041 0.119
GE - F 1.013 8.0% 9.2% 0.235 0.170 0.085 0.099
GE - G 0.951 5.5% 6.6% 0.274 0.203 0.129 0.094
Philips - A 1.146 7.2% 15.0% 0.176 0.204 0.103 0.218
Philips - B 1.061 3.7% 5.2% 0.267 0.232 0.150 0.197
Siemens 1 - A 1.555 10.1% 20.3% 0.126 0.566 0.139 0.574
Siemens 1 - B 1.477 8.0% 19.1% 0.116 0.487 0.112 0.505
Siemens 1 - C 1.325 5.4% 12.5% 0.148 0.346 0.104 0.375
Siemens 1 - D 1.094 3.9% 7.9% 0.218 0.179 0.080 0.165
Siemens 1 - E 0.948 2.7% 4.9% 0.290 0.199 0.145 0.084
Siemens 2 - A 1.045 3.7% 5.4% 0.246 0.184 0.104 0.138
Min 0.948 2.7% 4.9% 0.076 0.157 0.036 0.084
Max 1.555 17.8% 20.4% 0.290 0.566 0.150 0.574
Average 1.159 7.9% 12.3% 0.187 0.253 0.094 0.231
COVMCR
15.4%
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SUVmax and SUVpeak ranged from 2.7% to 5.3%, 3.7% to
8.0% and 2.8% to 3.0%, respectively. The CRVshort results for
SUVmean, SUVmax and SUVpeak ranged from 2.3% to
6.2%, 5.2% to 9.2% and 2.9% to 5.8%, respectively
(Tables 6, 7 and 8).
Noise
The CoVBG values are summarised in supplemental Fig. 8. The
average CoVBG of all reconstruction modes with a long time
frame was 12.6%. For medium and short acquisition times, the
corresponding values were 19.7% and 27.0%, respectively. The
selected reconstruction modes for harmonisation purposes pro-
duced average CoVBG values of 9.4%, 14.0% and 18.4% for
long, medium and short acquisition time frames, respectively.
Curvature and absolute error
Curvatures for the initial 15 reconstruction modes were in the
ranges of 0.031–0.269, 0.076–0.290 and 0.305–0.413 for
Table 5 Analysis results of 15 initial reconstruction modes using SUVpeak quantitative metric
Reconstruction mode MCR CRVmedium CRVshort Curvature Absolute error Curvature
(excl. 10 mm sphere)
Absolute error
(excl. 10 mm sphere)
GE - A 0.848 3.9% 3.7% 0.334 0.287 0.187 0.153
GE - B 0.833 3.4% 5.7% 0.381 0.310 0.237 0.179
GE - C 0.840 2.3% 3.6% 0.359 0.302 0.211 0.166
GE - D 0.823 3.9% 6.3% 0.389 0.320 0.248 0.191
GE - E 0.821 2.9% 4.1% 0.400 0.339 0.250 0.203
GE - F 0.784 3.3% 5.8% 0.404 0.346 0.272 0.223
GE - G 0.757 3.1% 5.9% 0.413 0.367 0.287 0.248
Philips - A 0.874 3.2% 3.4% 0.328 0.281 0.192 0.161
Philips - B 0.796 2.8% 2.9% 0.383 0.341 0.263 0.229
Siemens 1 - A 0.901 4.5% 6.3% 0.305 0.232 0.148 0.090
Siemens 1 - B 0.929 1.6% 4.2% 0.325 0.240 0.154 0.103
Siemens 1 - C 0.872 3.3% 5.0% 0.308 0.251 0.151 0.107
Siemens 1 - D 0.823 3.0% 4.5% 0.350 0.291 0.204 0.155
Siemens 1 - E 0.754 3.9% 2.7% 0.382 0.346 0.255 0.226
Siemens 2 - A 0.789 2.9% 4.9% 0.355 0.323 0.240 0.214
Min 0.754 1.6% 2.7% 0.305 0.232 0.148 0.090
Max 0.929 4.5% 6.3% 0.413 0.367 0.287 0.248
Average 0.830 3.2% 4.6% 0.361 0.305 0.220 0.177
COVMCR 6.0%
Table 6 Results of the analysis of five reconstruction modes considered for harmonisation using the SUVmean quantitative metric
Reconstruction mode MCR CRVmedium CRVshort Curvature Absolute error Curvature
(excl. 10 mm sphere)
Absolute error
(excl. 10 mm sphere)
GE - E 0.806 5.2% 6.2% 0.218 0.253 0.075 0.134
GE - F 0.770 5.3% 5.3% 0.228 0.277 0.120 0.183
Philips - B 0.800 2.7% 2.3% 0.236 0.271 0.124 0.165
Siemens 1 - D 0.816 2.9% 5.1% 0.197 0.222 0.097 0.138
Siemens 2 - A 0.804 3.0% 4.4% 0.203 0.238 0.100 0.150
Min 0.770 2.7% 2.3% 0.197 0.222 0.075 0.134
Max 0,816 5.3% 6.2% 0.236 0.277 0.124 0.183
Average 0.799 3.8% 4.6% 0.216 0.252 0.103 0.154
COVMCR 2.2%
EARL min 0.570 N/A N/A 0.282 0.466 0.198 0.393
EARL max 0.710 N/A N/A 0.277 0.342 0.176 0.251
EARL Average 0.640 N/A N/A 0.279 0.403 0.187 0.321
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SUVmean, SUVmax and SUVpeak, respectively. For the five
reconstruction modes suggested for harmonisation, the
SUVmean, SUVmax and SUVpeak curvatures were in the
ranges of 0.197–0.236, 0.212–0.267 and 0.350–0.404,
respectively.
Absolute errors for the initial 15 reconstruction modes were
in the ranges of 0.053–0.329, 0.157–0.566 and 0.232–0.367 for
SUVmean, SUVmax and SUVpeak, respectively. For the five
reconstruction modes selected for harmonisation, the
SUVmean, SUVmax and SUVpeak curvatures ranged between
0.222–0.277, 0.170–0.232 and 0.291–0.346, respectively.
Visual analysis
Significant variations in investigated RC curves’ shapes and
positions of Siemens 1 - A, B, C, GE - A, B, C, D and Philips –
A reconstruction modes were noticed when compared with
other systems or acquisition times and considered unsuitable
for harmonisation. Based on the bandwidth and characteristics
of harmonising reconstruction modes, quantitative cut-off
criteria were determined and are stated in Table 9.
Additional reconstructions
Sixteen EARL accredited sites participated in the prospec-
tive evaluation of the newly proposed specifications for
harmonisation and performed reconstructions according to
instructions provided. Data received included 23 distinctive
reconstructions from three GE Discovery 710 systems, two
Philips Ingenuity systems, six Siemens mCT systems,
three Siemens mCT Flow systems, one GE Discovery IQ
system, two GE Discovery MI systems and one Philips
Vereos system. RC curves derived from the 18 systems
along with proposed new harmonising specifications can
be seen in Fig. 3. For SUVmean, 16 out of 138 analysed
spheres produced RC values outside of the suggested
Table 7 Results of the analysis of five reconstruction modes considered for harmonisation using the SUVmax quantitative metric
Reconstruction mode MCR CRVmedium CRVshort Curvature Absolute error Curvature
(excl. 10 mm sphere)
Absolute error
(excl. 10 mm sphere)
GE - E 1.036 7.2% 7.7% 0.212 0.178 0.041 0.119
GE - F 1.013 8.0% 9.2% 0.235 0.170 0.085 0.099
Philips - B 1.061 3.7% 5.2% 0.267 0.232 0.150 0.197
Siemens 1 - D 1.094 3.9% 7.9% 0.218 0.179 0.080 0.165
Siemens 2 - A 1.045 3.7% 5.4% 0.246 0.184 0.104 0.138
Min 1.013 3.7% 5.2% 0.212 0.170 0.041 0.099
Max 1.094 8.0% 9.2% 0.267 0.232 0.150 0.197
Average 1.050 5.3% 7.1% 0.236 0.189 0.092 0.144
COVMCR 2.9%
EARL min 0.730 N/A N/A 0.347 0.355 0.220 0.237
EARL max 0.970 N/A N/A 0.339 0.236 0.176 0.121
EARL Average 0.850 N/A N/A 0.342 0.277 0.198 0.142
Table 8 Results of the analysis of five reconstruction modes considered for harmonisation using the SUVpeak quantitative metric
Reconstruction mode MCR CRVmedium CRVshort Curvature Absolute error Curvature
(excl. 10 mm sphere)
Absolute error
(excl. 10 mm sphere)
GE - E 0.821 2.9% 4.1% 0.400 0.339 0.250 0.203
GE - F 0.784 3.3% 5.8% 0.404 0.346 0.272 0.223
Philips - B 0.796 2.8% 2.9% 0.383 0.341 0.263 0.229
Siemens 1 - D 0.823 3.0% 4.5% 0.350 0.291 0.204 0.155
Siemens 2 - A 0.789 2.9% 4.9% 0.355 0.323 0.240 0.214
Min 0.784 2.8% 2.9% 0.350 0.291 0.204 0.155
Max 0.823 3.3% 5.8% 0.404 0.346 0.272 0.229
Average 0.803 3.0% 4.4% 0.378 0.328 0.246 0.205
COVMCR 2.2%
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accreditation interval, while for SUVmax and SUVpeak,
the number of outliers was 12. Quantitative results de-
scribing additional reconstructions can be found in
Tables 10, 11 and 12. Specifications, based on the current
findings, proposed for harmonisation along with current
EARL specifications are presented in Table 13.
Discussion
The SUVmean and SUVmax RC curves of the initial 15 re-
construction modes vary significantly, even within one sys-
tem. This reflects the high degree of variability that could be
introduced into quantitative PETwith variation in reconstruc-
tion settings. The selection of harmonising reconstruction
modes, and the validation which followed on additional re-
constructions, demonstrated that the variability can be reduced
to acceptable limits.
The acquisition time of 5 min per bed position specified in
the current EARL accreditation settings, while characterising
system performance in high statistics scenarios, may not pro-
vide an accurate representation of the reconstruction mode’s
performance in clinical settings. Therefore, the observation of
reduced CRVmedium and CRVshort in reconstruction modes for






































































Fig. 3 RC curves derived from additional reconstructions using
SUVmean (a), SUVmax (b) and SUVpeak (c) quantitative metrics
along with proposed new specifications. GE (Q.Clear) – blue dashed
lines, GE (non-Q.Clear) – blue solid lines, Philips – red solid lines,
Siemens – orange solid lines, possible new EARL specifications –
black dashed lines
Table 9 Retrospectively determined quantitative cut-off criteria for the
harmonising reconstructions
SUVmean SUVmax
MCR ±11% (0.77–0.96) ±13% (1.01–1.31)
CRVmedium 6% 8%
CRVshort 7% 9%
Visual analysis No excessive Gibbs and partial volume artefacts
Noise Background CoV ≤15% (high statistics acquisition)
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utilising new PET/CT systems are routinely reduced to 2 min
or less per bed position.
Significant increase in both SUVmean and SUVmaxMCR
values was observed in the reconstruction modes proposed for
harmonisation compared to the corresponding current EARL
specifications. The trend is in agreement with results recently
published by Sunderland et al. demonstrating that high-end
PET/CT systems are having significantly increased SUVmax
values in anthropomorphic phantom scans [53]. The metrics
for all of the spheres demonstrated a noticeable increase; how-
ever, for the smaller spheres (≤ 17 mm) the effect was rela-
tively stronger. This could be explained by the so-called Gibbs
artefact which produces an overshoot of measured activity at
the edges of the spheres, becoming more dominant at smaller
sizes, also described by Lasnon et al. [54]. To some extent the
effect can be considered beneficial, compensating for the in-
herently lower recoveries seen in the smaller spheres. It
should, however, be noticed that with the use of resolution
modelling (PSF) without any or with minimal post filtering
applied, the overshoot could introduce significant positive
SUV bias, in particular when using SUVmax. Methods like
regularised (MAP) reconstruction with a regularising prior
(such as Q.Clear implemented by GE) can also be used to
suppress Gibbs artefacts and were therefore also considered
in this study.
The increased SUVmean and SUVmax recoveries seen in
the proposed reconstruction modes for harmonisation would
significantly reduce the gap that exists today between
standardised quantitative reconstruction protocols used in
multicentre settings and the locally developed non-standard
protocols for lesion detection and general visual assessment
– both of which are used in parallel in many nuclear medicine
departments. Close agreement between the two could lead to
the adoption of a single reconstruction mode that would pro-
vide standardised SUV data while maintaining increased le-
sion detectability.
In the reconstruction modes identified as suitable candidates
for harmonisation, a relatively higher increase was found in the
Table 10 Analysis results of 23 additional reconstructions using the SUVmean quantitative metric
PET/CT system MCR CRVmedium CRVshort Curvature Absolute error Curvature
(excl. 10 mm sphere)
Absolute error
(excl. 10 mm sphere)
Ingenuity 1 0.820 N/A N/A 0.213 0.249 0.106 0.145
Ingenuity 2 0.694 N/A N/A 0.276 0.365 0.164 0.263
mCT Flow 1 0.691 N/A N/A 0.303 0.368 0.196 0.270
mCT Flow 2 0.711 N/A N/A 0.298 0.339 0.190 0.242
mCT Flow 3 0.816 N/A N/A 0.193 0.231 0.079 0.136
mCT 1 0.847 N/A N/A 0.176 0.194 0.080 0.112
mCT 2 0.786 N/A N/A 0.194 0.250 0.115 0.181
mCT 3 0.825 N/A N/A 0.188 0.208 0.113 0.142
mCT 4 0.765 N/A N/A 0.174 0.262 0.091 0.195
mCT 5 0.786 N/A N/A 0.195 0.245 0.119 0.179
mCT 6 0.811 N/A N/A 0.136 0.207 0.078 0.161
Discovery 710 1 0.847 N/A N/A 0.153 0.182 0.079 0.120
Discovery 710 2 0.793 N/A N/A 0.217 0.254 0.129 0.174
Discovery 710 1 Q.Clear 1 0.887 N/A N/A 0.120 0.145 0.027 0.074
Discovery 710 2 Q.Clear 2 0.817 N/A N/A 0.211 0.236 0.110 0.146
Discovery 710 3 Q.Clear 3 0.895 N/A N/A 0.121 0.144 0.042 0.073
GE Discovery MI 1 0.794 N/A N/A 0.150 0.228 0.099 0.182
GE Discovery MI 2 0.813 N/A N/A 0.171 0.214 0.102 0.155
GE Discovery MI 1 Q.Clear 1 0.857 N/A N/A 0.081 0.151 0.055 0.129
GE Discovery MI 2 Q.Clear 2 0.869 N/A N/A 0.118 0.156 0.039 0.096
GE Discovery IQ 1 0.817 N/A N/A 0.219 0.244 0.077 0.123
GE Discovery IQ 1 Q.Clear 1 0.818 N/A N/A 0.221 0.246 0.069 0.118
Vereos 1 0.757 N/A N/A 0.191 0.277 0.087 0.195
Min 0.691 0.081 0.144 0.027 0.073
Max 0.895 0.303 0.368 0.196 0.270
Average 0.805 0.188 0.235 0.098 0.157
COVMCR 6.6%
Eur J Nucl Med Mol Imaging (2018) 45:1344–1361 1355
recoveries of smaller spheres. This would lead to more Bflat^
RC curves, making subsequent quantitative analysis less de-
pendent on lesion size. With the proposed reconstruction
modes, the recoveries remained largely size-independent for
≥17 mm diameter lesions. Moreover, it is important to notice
that a possible new harmonising standard for systems with PSF
implies SUVmax recoveries to exceed 1.0. This suggests that if
SUVmax remains the de facto field standard for PET/CT quan-
tification, one should accept a positive bias of about 10 to 25%
for larger homogeneous objects (≥17 mm diameter).
For both SUVmean and SUVmax the proposed reconstruc-
tion modes for harmonisation yielded promising results. The
two largest spheres (28 mm diameter, 37 mm diameter)
showed excellent agreement across all systems for both
SUVmean and SUVmax. Even though there is not enough
data for a reproducibility assessment, it can be predicted that
a harmonising performance bandwidth is feasible for the next
generation of PET/CT systems. The results from prospective
validation using additional reconstructions will be further
improved in the EARL accreditation process, where the cen-
tres will be guided to optimise their reconstruction settings in
order to meet the new specifications.
As the harmonising RCs for SUVmean, SUVmax and
SUVpeak all demonstrated a noticeable curve, the curvature
and absolute error parameters exhibited increased or similar
values with the initial reconstruction modes. Calculations ex-
cluding the smallest sphere demonstrated much better perfor-
mance, which illustrated the high impact the smallest sphere
has, that led to a significant decrease in the RCs range.
The utility of the SUVpeak was investigated as being a
possible metric for standardised quantification. A recent pro-
spective repeatability study by Kramer et al. [55] demonstrat-
ed the robustness of using the SUVpeak in non–small cell
lung cancer patients. As previously shown by Makris et al.
[56], and presented in supplemental Figs. 4–6, SUVpeak is
significantly less sensitive to changes in reconstruction param-
eters and acquisition durations than SUVmean or SUVmax.
The difference is mostly prominent in the initial group of 15
Table 11 Analysis results of 23 additional reconstructions using the SUVmax quantitative metric
PET/CT system MCR CRVmedium CRVshort Curvature Absolute error Curvature
(excl. 10 mm sphere)
Absolute error
(excl. 10 mm sphere)
Ingenuity 1 1.094 N/A N/A 0.278 0.264 0.143 0.228
Ingenuity 2 0.917 N/A N/A 0.334 0.288 0.188 0.167
mCT Flow 1 0.911 N/A N/A 0.347 0.270 0.207 0.159
mCT Flow 2 0.943 N/A N/A 0.350 0.234 0.187 0.109
mCT Flow 3 1.071 N/A N/A 0.237 0.211 0.110 0.179
mCT 1 1.118 N/A N/A 0.185 0.179 0.057 0.179
mCT 2 1.038 N/A N/A 0.173 0.140 0.065 0.108
mCT 3 1.098 N/A N/A 0.168 0.148 0.082 0.151
mCT 4 1.019 N/A N/A 0.160 0.130 0.041 0.082
mCT 5 1.033 N/A N/A 0.176 0.127 0.067 0.092
mCT 6 1.067 N/A N/A 0.113 0.107 0.033 0.105
Discovery 710 1 1.139 N/A N/A 0.151 0.176 0.051 0.188
Discovery 710 2 1.045 N/A N/A 0.213 0.168 0.086 0.130
Discovery 710 1 Q.Clear 1 1.172 N/A N/A 0.085 0.189 0.054 0.207
Discovery 710 2 Q.Clear 2 1.049 N/A N/A 0.204 0.172 0.064 0.131
Discovery 710 3 Q.Clear 3 1.154 N/A N/A 0.114 0.184 0.042 0.200
GE Discovery MI 1 1.055 N/A N/A 0.105 0.100 0.032 0.095
GE Discovery MI 2 1.066 N/A N/A 0.179 0.142 0.065 0.125
GE Discovery MI 1 Q.Clear 1 1.119 N/A N/A 0.040 0.123 0.017 0.108
GE Discovery MI 2 Q.Clear 2 1.124 N/A N/A 0.107 0.157 0.039 0.168
GE Discovery IQ 1 1.102 N/A N/A 0.255 0.240 0.047 0.201
GE Discovery IQ 1 Q.Clear 1 1.083 N/A N/A 0.234 0.219 0.052 0.177
Vereos 1 1.029 N/A N/A 0.230 0.176 0.074 0.115
Min 0.911 0.040 0.100 0.017 0.082
Max 1.172 0.350 0.288 0.207 0.228
Average 1.063 0.193 0.180 0.078 0.148
COVMCR 6.3%
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relatively loosely selected reconstruction modes, while within
the five reconstructions for harmonisation and 23 additional
ones, the difference became less apparent. On the other hand,
the benefits of SUVpeak were offset by its consistently low
recoveries for spheres with ≤17 mm diameter and therefore
low MCR, which is comparable to that of SUVmean but sig-
nificantly (20–40%) lower than that of SUVmax. This is due
to peak VOI size approaching or even exceeding the size of
the sphere, therefore missing some of the active volume. If this
issue could be addressed by, for example, reducing the
SUVpeak VOI size, SUVpeak may be become an effective
alternative to SUVmax, especially if quantitative comparison
among reconstructions of unknown origin or non-harmonised
PET/CT systems is desired. Harmonisation among systems
Table 12 Analysis results of 23 additional reconstructions using SUVpeak quantitative metric
PET/CT system MCR CRVmedium CRVshort Curvature Absolute error Curvature
(excl. 10 mm sphere)
Absolute error
(excl. 10 mm sphere)
Ingenuity 1 0.789 N/A N/A 0.376 0.341 0.246 0.218
Ingenuity 2 0.736 N/A N/A 0.405 0.383 0.284 0.267
mCT Flow 1 0.737 N/A N/A 0.439 0.390 0.324 0.280
mCT Flow 2 0.750 N/A N/A 0.476 0.379 0.353 0.263
mCT Flow 3 0.797 N/A N/A 0.393 0.328 0.274 0.217
mCT 1 0.858 N/A N/A 0.348 0.282 0.214 0.162
mCT 2 0.812 N/A N/A 0.347 0.302 0.225 0.188
mCT 3 0.847 N/A N/A 0.365 0.281 0.242 0.169
mCT 4 0.781 N/A N/A 0.326 0.313 0.198 0.192
mCT 5 0.803 N/A N/A 0.355 0.304 0.243 0.199
mCT 6 0.827 N/A N/A 0.297 0.269 0.184 0.163
Discovery 710 1 0.829 N/A N/A 0.357 0.301 0.234 0.188
Discovery 710 2 0.794 N/A N/A 0.398 0.342 0.274 0.227
Discovery 710 1 Q.Clear 1 0.867 N/A N/A 0.372 0.294 0.231 0.171
Discovery 710 2 Q.Clear 2 0.824 N/A N/A 0.413 0.344 0.276 0.221
Discovery 710 3 Q.Clear 3 0.884 N/A N/A 0.370 0.298 0.212 0.166
GE Discovery MI 1 0.797 N/A N/A 0.351 0.313 0.233 0.202
GE Discovery MI 2 0.819 N/A N/A 0.375 0.308 0.237 0.180
GE Discovery MI 1 Q.Clear 1 0.838 N/A N/A 0.328 0.285 0.200 0.166
GE Discovery MI 2 Q.Clear 2 0.859 N/A N/A 0.356 0.294 0.202 0.157
GE Discovery IQ 1 0.814 N/A N/A 0.407 0.342 0.263 0.210
GE Discovery IQ 1 Q.Clear 1 0.831 N/A N/A 0.412 0.336 0.258 0.199
Vereos 1 0.803 N/A N/A 0.381 0.320 0.251 0.199
Min 0.736 0.297 0.269 0.184 0.157
Max 0.884 0.476 0.390 0.353 0.280
Average 0.813 0.376 0.320 0.246 0.200
COVMCR 4.7%
Table 13 SUVmean, SUVmax and SUVpeak specifications proposed for harmonisation along with current EARL specifications
Sphere diameter
(mm)
Current EARL RC bandwidth Proposed RC bandwidth
SUVmean SUVmax SUVpeak SUVmean SUVmax SUVpeak
37 0.76–0.89 0.95–1.16 N/A 0.85–1,00 1.05–1.29 0.99–1.07
28 0.72–0.85 0.91–1.13 N/A 0.82–0.97 1.01–1.26 0.95–1.07
22 0.63–0.78 0.83–1.09 N/A 0.80–0.99 1.01–1.32 0.90–1.09
17 0.57–0.73 0.73–1.01 N/A 0.76–0.97 1.00–1.38 0.75–0.99
13 0.44–0.60 0.59–0.85 N/A 0.63–0.86 0.85–1.22 0.45–0.69
10 0.27–0.43 0.34–0.57 N/A 0.39–0.61 0.52–0.88 0.27–0.41
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remains necessary in order to enable reliable use of SUVmax.
Further studies are needed in order to explore the optimal peak
VOI diameter maintaining noise cancelling effects, while pro-
ducing higher, yet harmonised recoveries.
An alternative to the described methodology of achieving
harmonised recoveries, such as suggested in this paper, could
be to gradually increase the post smoothing on high recovery
PET data until harmonised RC-s are obtained (supplemental
Figs. 9–11). Such a method is available on some systems and
previously validated by Lasnon et al. [54]. Potentially a post-
smoothing feature on a workstation could be used for this
purpose. This could result in higher recoveries and may re-
duce noise and Gibbs artefacts to acceptable levels for
multicentre harmonisation. However, when offline post-
smoothing needs to be applied to a dataset in order for it to
achieve quantitative harmonisation, the filter information for
the specific system always needs to accompany the PET data
and extra care be taken that the filter be actually applied and
clearly reported every time when required.
Limitations and future directions
Quantification of PET images is affected by uncertainties de-
rived from reconstruction settings as well as global system
(cross-) calibration. In this study the experimental data were
corrected for global calibration errors, but in clinical practice
both effects should be taken into consideration. Therefore, an
accurate system calibration remains of utmost importance for
all PET/CT systems used for quantification in order to keep
the uncertainties as low as possible.
The phantom experiments conducted were sensitive to
measurement uncertainties of dose calibrators and human er-
ror during the phantom preparation phase. The uncertainties
related to phantom filling procedure are not part of this study
and may increase the bandwidth of achievable harmonisation.
All experiments on various PET/CT models were per-
formed on appointed systems. The inter-system variability
stemming from the individual differences among the systems
of the same make and differences due to manufacturers
allowed variability in well counter calibration factors, and
may increase the bandwidth of achievable harmonisation even
further, although the newly proposed harmonisation specifica-
tion was set using the same bandwidth as current EARL,
which was shown to be appropriate and feasible.
As the position of VOI-s used in the analysis and compar-
ison of SUVmean data is based on PET images rather that CT
data, it is to some extent affected by image noise and may
induce a small additional uncertainty to the results. This, how-
ever, is reflective of the clinically used method of VOI posi-
tioning. When this strategy is followed, it is therefore impor-
tant to also put a threshold on acceptable noise levels (in this
paper background noise should be lower than 15%). Yet, use
of CT-based VOI definition could be of interest in order to
mitigate the effects of noise on VOI definition and subse-
quently on the measurement of the recovery coefficients.
Another alternative could be the use of SUVpeak rather than
SUVmax as a starting point for VOI definition, as was applied
in Frings et al. [57]. These strategies may be considered when
developing future standards.
Current study investigated harmonisation of PET/CT sys-
tems using 18F tracer based FDG. The results cannot be di-
rectly transferred to system performance harmonisation in-
volving other PET isotopes such as 68Ga or 82Rb which have
a substantially longer positron range. System performance
harmonisation with positron emitting isotopes other then18F
requires further investigation.
In this feasibility studywe primarily made use of reconstruc-
tion methods and parameter settings that were predefined or
could be easily set by the user on commercially released sys-
tems. Where the software permitted, we applied additional re-
constructions to include at least PSF and TOF, and also tried
other reconstruction parameter settings which were expected to
yield higher recoveries than the current EARL specification.
Yet, in this study we did not extensively explore a wide range
of reconstruction settings as, e.g., iterations, subsets, matrix
sizes, etc., since our aim was to investigate clinically available
protocols which are accessible for the users. Moreover, the
investigated reconstruction modes had similar, but still differ-
ent, voxel sizes as well as the number of iterations/subsets
between various systems which complicates direct comparison.
In conclusion, the harmonisation investigated in this study
should be considered as a first feasibility test aiming at improv-
ing the current EARL specifications. Of course, a higher level
of harmonisation would also be possible by considering more
parameters, but then the question will be the feasibly in clinical
practice. Further work is also needed to more extensively ex-
plore the impact of PSF reconstructions, voxel size and number
of iterations/subsets on the variability of quantitative metrics of
clinical datasets. Some reports have already been published
showing that the repeatability and ICC of SUVmax,
SUVpeak and SUVmean are at an acceptable level [58].
To conclude, despite possible limitations, we have studied the
feasibility of the harmonising state of the art PET/CT system
performances, and the results suggest that an update of the
EARL current specification is feasible and achievable in practice.
Conclusions
This study investigated the feasibility of harmonising perfor-
mance for PET/CT systems equipped with the latest Time-of-
Flight (ToF) and resolutionmodelling (PSF) technology. Also,
new possible specifications with higher contrast recoveries
were investigated using various metrics such as average, max-
imum and peak SUV. Harmonising state of the art PET/CT
systems with ToF and PSF technologies was found to be
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feasible. The harmonisation of such systems would require an
update to the current multicentre accreditation program of
EARL in order to accommodate higher recoveries. SUVpeak
could be used as an uptake metric being less sensitive to noise
and variation in image quality resulting from different recon-
struction settings. It could be considered as an alternative to
SUVmax if lower recoveries are considered to be acceptable
for lesions of 17 mm in diameter and smaller.
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